Recombinant Human Calcitonin gene-related peptide type 1 receptor (CALCRL)

What is CALCRL and what are its primary functions?

CALCRL, also known as calcitonin receptor-like receptor (CRLR), is a G protein-coupled receptor related to the calcitonin receptor. It functions as an essential component of receptors for calcitonin gene-related peptide and adrenomedullin. The CALCRL protein requires interaction with one of three single transmembrane domain receptor activity-modifying proteins (RAMPs) to achieve functional activity .

The association of CALCRL with different RAMP proteins produces distinct receptors with varying ligand specificities:

• CALCRL + RAMP1: forms a CGRP receptor

• CALCRL + RAMP2: forms an adrenomedullin (AM) receptor, designated AM1

• CALCRL + RAMP3: forms a dual CGRP/AM receptor designated AM2

These receptors are coupled to the G protein Gs, which activates adenylate cyclase, resulting in the generation of intracellular cyclic adenosine monophosphate (cAMP). CGRP receptors are distributed throughout the body, indicating that CALCRL may modulate various physiological functions across major systems including respiratory, endocrine, gastrointestinal, immune, and cardiovascular systems .

How is the structure of CALCRL characterized?

CALCRL, when associated with RAMP1 to form the CGRP receptor, is a transmembrane protein receptor composed of four chains. Two of these chains contain unique sequences, making it a heterodimer protein with two polypeptide chains that differ in their amino acid residue composition .

The protein sequence reveals multiple hydrophobic and hydrophilic regions distributed throughout the four chains. CALCRL can couple to multiple G-protein subunits including Gαs, Gαi, and Gαq to transduce signals across the cell membrane .

What methods are commonly used to study CALCRL expression in clinical samples?

CALCRL expression in clinical samples is typically analyzed using several complementary techniques:

How does CALCRL expression change during disease progression and treatment?

Research has shown that CALCRL expression demonstrates dynamic changes during disease progression and in response to treatment:

In AML/ETO+ AML patients, higher mRNA levels of CALCRL are observed before treatment initiation. Following successful treatment with multiple chemotherapy sessions resulting in complete remission, CALCRL expression levels significantly decrease . This pattern suggests that CALCRL expression correlates with disease activity and may serve as a potential marker for treatment response and minimal residual disease monitoring.

The prognostic impact of CALCRL expression remains consistent across different patient subgroups when analyzed by age, sex, white blood cell count, genetic risk factors, and treatment protocols, indicating that it represents a robust prognostic marker independent of these variables .

What is the role of CALCRL in hematological malignancies, particularly in AML?

CALCRL has emerged as a significant factor in the pathophysiology and prognosis of acute myeloid leukemia. Advanced research indicates that CALCRL functions as:

The table below summarizes the multivariate analysis of CALCRL expression as an independent prognostic factor in pediatric AML:

Data adapted from multivariable analysis adjusting for age, white blood cell count, and genetic risk factors

How does CALCRL interact with other genetic factors in determining AML outcomes?

CALCRL's prognostic significance interacts with other genetic and clinical factors in complex ways:

Research shows that integrating CALCRL expression assessment into existing risk stratification models can enhance prognostic accuracy and potentially guide therapeutic decision-making.

What experimental models are available for studying CALCRL function in hematological malignancies?

Several experimental models have been developed to study CALCRL function in hematological contexts:

• Knockout models: CALCRL knockout models in human AML cell lines have demonstrated reduced colony formation, confirming a functional role of the receptor in AML pathophysiology . These models allow for mechanistic studies of how CALCRL influences leukemic cell growth and survival.

• Gene expression profiling: Analysis of differential gene expression associated with CALCRL levels has identified 2,262 genes that are differentially expressed in correlation with CALCRL, with 516 upregulated and 1,746 downregulated . This approach helps identify downstream pathways and potential therapeutic targets.

• Patient-derived samples: The use of primary patient samples with varying levels of CALCRL expression enables translational research connecting molecular mechanisms to clinical outcomes. In particular, comparing samples before treatment and after achieving complete remission provides insights into CALCRL's role in disease dynamics .

• Receptor signaling assays: As CALCRL forms functional receptors with different RAMPs, assays measuring cAMP generation and other downstream signals can assess receptor functionality and response to potential therapeutic interventions .

These models collectively provide a comprehensive toolkit for investigating CALCRL biology from molecular mechanisms to clinical applications.

How might CALCRL be targeted therapeutically in hematological diseases?

Based on current research, several approaches to targeting CALCRL therapeutically show promise:

• Direct receptor antagonism: Developing antagonists that block the interaction between CALCRL and its ligands (CGRP and adrenomedullin) could potentially reduce its signaling activity. This approach has been explored in preclinical models of solid malignancies with demonstrated therapeutic activity .

• RAMP interaction inhibition: Since CALCRL requires association with RAMPs for functional activity, disrupting these protein-protein interactions represents a potential therapeutic strategy. This would prevent formation of functional receptor complexes .

• Downstream signaling inhibition: Targeting the G protein-coupled signaling pathways activated by CALCRL, such as adenylate cyclase activation and cAMP generation, could block the consequences of CALCRL overexpression .

• Combination with standard therapies: Given that high CALCRL expression correlates with chemotherapy resistance, combining CALCRL inhibition with standard chemotherapy might enhance treatment efficacy, particularly in high-risk patients .

• Stratified treatment approaches: Using CALCRL expression as a biomarker to identify patients who might benefit from more intensive therapies, including hematopoietic stem cell transplantation, could improve outcomes in high-risk subgroups .

What techniques can be used to produce and purify recombinant CALCRL for structural and functional studies?

Producing recombinant CALCRL for research purposes requires specialized techniques due to its nature as a multi-spanning membrane protein:

• Expression systems: Mammalian cell expression systems (e.g., HEK293, CHO cells) are preferred for CALCRL expression as they provide appropriate post-translational modifications and membrane insertion machinery. Insect cell systems (Sf9, High Five) may also be used for higher yield.

• Co-expression strategies: Since functional CALCRL requires association with RAMPs, co-expression of both proteins is necessary to study the receptor in its physiologically relevant form. This can be achieved using bicistronic vectors or co-transfection approaches.

• Affinity purification: Adding epitope tags (His, FLAG, etc.) to the recombinant CALCRL facilitates affinity purification. For structural studies, fusion proteins such as T4 lysozyme or BRIL may be incorporated to stabilize the receptor.

• Detergent solubilization: As a membrane protein, CALCRL requires careful detergent solubilization for extraction from cell membranes. Mild detergents like DDM, LMNG, or digitonin are commonly used to maintain protein structure and function.

• Reconstitution systems: For functional studies, purified CALCRL can be reconstituted into artificial membrane systems such as nanodiscs, liposomes, or lipid cubic phase to provide a native-like environment.

• Functional validation: Recombinant CALCRL should be validated for proper folding and function using ligand binding assays, G protein coupling assays, and downstream signaling detection (cAMP accumulation).

These techniques enable researchers to obtain purified CALCRL for structural studies, antibody generation, ligand screening, and mechanistic investigations that could lead to therapeutic development.